News

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia’s drug candidate EVX-101, which is in development for major depressive disorder (MDD).

BioPharm International: John McDermott on Drug Development Outsourcing

BioPharm International interviews our VP of Scientific Consulting, John McDermott, who discusses the latest trends in drug development outsourcing.

Quotient Sciences Presents at APS Basic Biopharmaceutics Workshop

Chris Roe, Principal Research Fellow, and Ricardo Diaz de Leon Ortega, Modelling and Simulation Research Fellow, attended and presented at the Basic Biopharmaceutics Workshop hosted by The Biopharmaceutics Focus Group of the Academy of Pharmaceutical Sciences UK in London.

Oxilio completes first clinical trial with OXL001 at Quotient Sciences - Nottingham

Oxilio Limited (“Oxilio”) reports favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001 in healthy male volunteers that is being conducted at Quotient Sciences.

3 Key Trends Shaping Our Industry: Contract Pharma Thought Leadership Feature with Eleanor Row

Quotient Sciences’ Executive Director of Commercial, Eleanor Row, offers her thought leadership in Contract Pharma on the 3 key trends shaping our industry.

Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial

Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.